A Message from Sanofi

Sanofi would like to reassure you and patients with insulin-dependent diabetes that we are not experiencing any shortages of insulin glargine 100 units/mL in Australia as aresult of the COVID-19 pandemic.

Sanofi has accelerated its supply of Optisulin (insulin glargine100 units/mL) in Australia to support the ongoing availability of insulin glargine 100 units/mL.


  • From July 1, 2020, Lantus will be delisted trom the Pharmaceutical Benefits Scheme (PBS).
  • From May 1, 2020, wholesalers will no longer supply pharmacies with Lantus , offering Optisulin as Sanofi’s only brand of insulin glargine 100 units/mL.

Therefore, over the coming period, it is likely patients prescribed Lantus will be transitioned to Optisulin or an alternative.

For more information contact Diabetes and Health Solutions